Introduction {#s1}
============

Sporadic colorectal cancer (CRC) is a common malignancy in the western world and one of the main causes of cancer deaths. The high mortality rate, due to occult or clinically identified disseminated disease already at diagnosis, emphasizes the importance of a higher understanding of the biological events leading to an invasive cancer. This knowledge is important to predict patient prognosis and create new, powerful therapies. The adenoma to carcinoma sequence depicture the genetic events needed for a normal colon epithelia to be transformed into a malignant phenotype in most of the sporadic CRC cases [@pone.0101957-Fearon1]. Since the metastatic process in CRC is not as fully understood, it is hard to elucidate why some tumors become more aggressive and metastasize more easily than others. Identification of molecular markers expressed in invasive tumors that can predict poor patient prognosis is therefore an important research subject.

SRY (sex determining region Y)-box 2 (SOX2) is a member of the large *SOX* gene family, comprising transcription factors known to be important in the regulation of developmental processes and cell type specification [@pone.0101957-Sarkar1]. The key member SOX2 plays essential roles in the maintenance of cell pluripotency and self-renewal in both embryonic stem cells [@pone.0101957-Avilion1] and in induced pluripotent stem cells [@pone.0101957-Takahashi1]. Recently it has also been reported that self-renewal of cancer stem cells is maintained by SOX2 [@pone.0101957-BasuRoy1], suggesting an ongogenic role of SOX2. Overexpression of SOX2 can be seen in CRC [@pone.0101957-Han1]--[@pone.0101957-Park1] as well as in several other malignancies such as breast, pancreatic and gastric cancers [@pone.0101957-RodriguezPinilla1]--[@pone.0101957-Li1], demonstrating its involvement in carcinogenesis. In addition, SOX2 has been suggested to be involved in CRC cell migration, invasion and metastasis, where matrix metalloproteinase 2 (MMP2) has been proposed as a potential mediator for the SOX2 effect [@pone.0101957-Han1], but the exact mechanisms still need to be discovered.

In the present study we evaluated SOX2 expression in primary CRC, as well as in samples of corresponding liver metastasis, and correlated our findings to patient prognosis and molecular tumor characteristics. Our results suggest that SOX2 expression is, at least partly, regulated by BRAF, and that expression of BRAF^V600E^ in a stage dependent manner correlates to a poor patient prognosis.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

In the present study, the handling of tissue samples and patient data was approved by the research ethical committee at Umeå University Hospital (Regional Ethical Review Board in Umeå, Sweden). This includes the procedure whereby patients verbally gave their informed consent, which was documented in each patient record and considered by the Ethics Committee to be sufficient. Each tissue sample was registered as a case number and year in the database used for the analyses, and names or personal identification were not indicated.

Clinical samples {#s2b}
----------------

The CRC tissue samples included in the study were from the Colorectal Cancer in Umeå Study (CRUMS), which consists of patients that have been surgically resected for primary CRC between 1995 and 2003 at Umeå University Hospital, Sweden. Histopathological classifications of all cases were performed by one pathologist by reviewing routinely stained tumor sections. Clinical data were obtained by reviewing the patient records, and survival data were collected during autumn 2012.

13 patients with archival tissue from both a primary colorectal adenocarcinoma and corresponding distant liver metastasis that were diagnosed in the same time interval as CRUMS were included in the present study. These were identified using the computerized patient record database at the Department of Clinical Pathology, Umeå University Hospital, Sweden. The tumors were graded and diagnosed by pathologists at the time of surgery or biopsy.

Immunohistochemistry {#s2c}
--------------------

CRC specimens were formalin-fixed and paraffin embedded according to routine protocols at the Department of Clinical Pathology, Umeå university Hospital, Sweden. They were cut at 4-µm and then dried, deparaffinized and rehydrated. Anti-SOX2 polyclonal antibody [@pone.0101957-Ruan1]--[@pone.0101957-Gallo1] (Abcam, Cambridge, UK) was used at a concentration of 1∶500 in a semiautomatic staining machine (Bench Mark Ultra, Ventana Inc) and visualized by iVIEW DAB Detection kit (Ventana Inc)). The slides were counterstained with hematoxylin.

For CRUMS, 449 cases were immunohistochemically stained, but due to lack of tumor material (n = 7) or repeated tissue loss during antigen retrieval step (n = 1), eight of them could not be analyzed for SOX2 staining. All the 13 patients with corresponding metastasis were successfully stained, and all could be analyzed for SOX2-positive cells. The specimens were reviewed under light microscopy, and each sample was evaluated two times by the same observer and in cases with discrepant scoring, a third final evaluation was made. Nuclear staining was assessed as negative or positive. Occasional cytoplasmic or stromal staining was not analyzed.

Statistical analyses {#s2d}
--------------------

Associations between SOX2 expression and different clinicopathological variables were analyzed using Pearson\'s χ^2^ tests. To estimate cancer-specific survival, Kaplan-Meier survival analysis was used, and comparisons between groups were made using the log-rank test. Patients in the CRUMS cohort who died within one month from surgery due to postoperative complications (n = 37) were excluded from the survival analyses. Cox proportional hazard models were used for multivariate analyses. Cancer-specific events were defined as death with known disseminated or recurrent disease, and cases were censored at the end of follow-up or at time of death by other causes. SPSS/PASW statistical software version 20 (SPSS Inc., Chicago, Illinois, USA) was used for the statistical analyses. Gene expression levels were compared using two tailed Student\'s *t* test. Each bar represents an average of three independent experiments and the error bars illustrate the standard deviation. *p*\<0.05 was considered statistically significant for all analyses.

Cell lines and cell culture {#s2e}
---------------------------

In the present study, the colon cancer cell line Caco2 (American Type Culture Collection, Manassas, VA, USA) was grown in Dulbecco\'s modified Eagle\'s medium (DMEM) with glutamax supplemented with 10% fetal bovine serum (FBS) (Gibco, Life Technologies, Stockholm, Sweden) and maintained at 37°C and 5% CO~2~. Generation of the stable transfectants expressing SOX2 (Caco2-SOX2), mutant BRAF (Caco2-BRAF^V600E^) or mutant KRAS (Caco2-KRAS^G12V^) was performed by transfecting Caco2-cells with pcDNA3.3-SOX2 (Derrick Rossi, Childrens Hospital Boston, USA, via Addgene), pMCEF-BRAFV^600E^ (kindly provided by Prof R. Marais) or pcDNA3-KRAS^G12V^ (kind gift from Dr N. Ignatenko) using Caco-2 Transfection Reagent (Altogen Biosystems, Las Vegas, NV, USA) according to the manufacturer\'s instructions. Between 48 and 72 hours after exposure to the DNA, transfected cells were selected with 800 µg/ml G418 (Gibco, Life Technologies, Stockholm, Sweden). Medium containing G418 was changed twice a week.

To block BRAF signaling in Caco2 and Caco2-BRAF^V600E^ cells, 20 µM MEK inhibitor PD98059 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or DMSO as control, was added to the cells following incubation for 24 or 48 h.

RT-PCR {#s2f}
------

Total RNA was isolated from cells using the NucleoSpin RNA II kit (Macherey-Nagel, Duren, Germany), and cDNA was synthesized with the SuperScript II Reverse Transcriptase (Invitrogen, Life Technologies, Stockholm, Sweden) according to manufacturer\'s protocols. Primers used in the study were from DNA Technology A/S (Aarhus, Denmark) and their sequences were as follows: GAPDH forward: 5′-TGCACCACCAACTGCTTAGC-3′, reverse: 5′-GGCATGGACTGTGGTCATGAG-3′. SOX2 forward: 5′-AACCCCAAGATGCACAACTC-3′, reverse: 5′-CGGGGCCGGTATTTATAATC-3′. FGFR1 forward: 5′-AGGCTACAAGGTCCGTTATGC-3′, reverse: 5′- TGCCGTACTCATTCTCCACAA-3′. FGFR2 forward: 5′-TTAAGCAGGAGCATCGCATTG-3′, reverse: 5′- GGGACCACACTTTCCATAATGAG-3′. FGFR3 forward: 5′-CCTCGGGAGATGACGAAGAC-3′, reverse: 5′-CGGGCCGTGTCCAGTAAGG-3′. FGFR4 forward: 5′-TGCAGAATCTCACCTTGATTACA-3′, reverse: 5′-GGGGTAACTGTGCCTATTCG-3′. Every PCR-reaction contained 25 ng cDNA and each sample was run in duplicates. The experiments were repeated three times. Standard deviations were calculated of the mean of triplicate reactions. The RT-PCR-reactions were performed on Taqman 7900HT (Applied Biosystems, Life Technologies, Stockholm, Sweden) and following cycling parameters were used: 50°C for 2 min and then an initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Gene expressions were normalized to GAPDH.

Western blot {#s2g}
------------

To analyze SOX2 expression in the stable Caco2-SOX2 transfectant, cells were lysed in lysis buffer (100 mM NaCl, 50 mM Tris pH 7.5, 1% Triton X-100, 1 mM EDTA pH 8.0, 15 mM MgCl~2~, protein inhibitors) before proteins were separated by SDS PAGE and transferred to a PVDF membrane (GE Healthcare, Uppsala, Sweden). The blot was incubated with primary SOX2 antibody (1∶1000, Cell Signaling Technology, Danvers, MA, USA) and secondary antibody conjugated to horseradish peroxidase (GE Healthcare, Uppsala, Sweden) according to manufacturer\'s instructions. The blot was developed with ECL Select Western Blotting Detection Reagent (GE Healthcare, Uppsala, Sweden).

Digital droplet PCR {#s2h}
-------------------

Genomic DNA was isolated from the cells using the Nucleospin Tissue kit (Macherey-Nagel, Duren, Germany) according to manufacturer\'s instructions.

Digital droplet PCR (ddPCR, Bio-Rad Laboratories, Hercules, CA, USA) was used to verify the Caco2 transfectants expressing mutant *BRAF^V600E^* (Caco2-BRAF^V600E^) and *KRAS^G12V^* (Caco2-KRAS^G12V^). The ddPCR-method has been presented thoroughly elsewhere [@pone.0101957-Hindson1], [@pone.0101957-Pinheiro1]. Briefly, the ddPCR allows detection and quantification of both mutation and wild type in the same reaction using the fluorophores FAM and HEX conjugated to sequence specific probes. In the ddPCR-method, a PCR sample of 20 µl is partitioned into 20 000 nanoliter droplets giving about 20 000 reads.

To verify a successful transfection of Caco2-BRAF^V600E^, the primers and probes were as follows: forward: 5′-GCACAGGGCATGGATTACTTACA-3′, reverse: 5′-ATCCAGACAACTGTTCAAACTGATG-3′, wild type probe: 5′-56-FAM/TTGGTCTAGCTACAGTGAAAT/3BHQ_1-3′, mutation probe: 5′-5HEX/TTGGTCTAGCTACAGAGAAAT/3BHQ_1-3′ (DNA Technology A/S, DNA Technology A/S) [@pone.0101957-Benlloch1], [@pone.0101957-Johnson1]. The PCR was performed in a T100 Thermal Cycler(Bio-Rad Laboratories, Hercules, CA, USA) using the program: 95°C for 10 min; 40x cycles of 95°C for 15 s and 56°C for 1 min (ramp rate 2°C/sec); and 98°C for 10 min. 900 nM of the primers, and 250 nM of respective probe was used.

For detection of successful transfection of Caco2-KRAS^G12V^, assays for ddPCR were used (PrimePCR ddPCR Mutation Assay: KRAS p.G12V assay, Human; PrimePCR ddPCR Mutation Assay: KRAS wild type for p.G12V assay, Human, Bio-Rad Laboratories, Hercules, CA, USA) with PCR-conditions according to manual provided by the company: 95°C for 10 min; 40x cycles of 94°C for 30 s and 55°C for 1 min (ramp rate 2°C/sec); and 98°C for 10 min.

Every PCR reaction contained 50 ng DNA and the droplets were prepared in a QX100 droplet generator (Bio-Rad Laboratories, Hercules, CA, USA). The final PCR-product was detected in a QX200 droplet reader (Bio-Rad Laboratories, Hercules, CA, USA) and the result analyzed with QuantaSoft software, Version 1.4 (Bio-Rad Laboratories, Hercules, CA, USA).

CpG island methylator phenotype (CIMP) status {#s2i}
---------------------------------------------

Tumor CIMP status was determined by the MethyLight method with primer and probe sequences that are previously described [@pone.0101957-Weisenberger1], [@pone.0101957-Dahlin1]. For the eight genes in the CIMP panel (*CDKN2A*, *MLH1*, *CACNA1G*, *NEUROG1*, *RUNX3*, *SOCS1*, *IGF2* and *CRABP1*) [@pone.0101957-Dahlin1] the percent of methylated reference (PMR) was calculated, where PMR \>10 was considered as positive [@pone.0101957-Weisenberger1]. Tumors were classified as CIMP negative (no promoter hypermethylation), CIMP low (one to five genes methylated) or CIMP high (six to eight genes methylated) [@pone.0101957-Dahlin1].

Microsatellite instability (MSI) screening status {#s2j}
-------------------------------------------------

Mismatch repair proteins were analyzed by immunohistochemistry as previously described [@pone.0101957-Dahlin1]. Briefly, formalin-fixed and paraffin embedded CRC tissue was examined for expression of four mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2). A sample considered having a positive MSI screening status lacked nuclear staining in tumor cells for at least one of the proteins and is referred to as MSI. A negative MSI screening status had expression of all four genes and was referred to as microsatellite stable (MSS).

BRAF^V600E^ mutational status {#s2k}
-----------------------------

The Taqman allelic discrimination assay, described in detail elsewhere [@pone.0101957-Benlloch1], was used for detection of the *BRAF^V600E^* mutation (reagents from Applied Biosystems, Life Technologies, Stockholm, Sweden).

KRAS sequencing {#s2l}
---------------

Mutational analysis of *KRAS* has been explained elsewhere [@pone.0101957-Eklof1]. The sequencing was carried out using Big Dye v. 3.1 (Applied Biosystems, Life Technologies, Stockholm, Sweden) and primers used were: forward: 5′-TGTAAAACGACGGCCAGTGAGTTTGTATTAAAAGGTACTGG-3′ and reverse: 5′-CAGGAAACAGCTATGACCTCTGTATCAAAGAATGGTCCT-3′.

Results {#s3}
=======

SOX2 expression in CRC correlates with tumor grade, TNM stage and *BRAF* mutation {#s3a}
---------------------------------------------------------------------------------

Nuclear SOX2 expression in tumor cells was evaluated in 441 CRC patient samples by immunohistochemistry, where the expression was assessed as either positive or negative ([Figure 1](#pone-0101957-g001){ref-type="fig"}). In the positive cases, SOX2 expression was never seen in the whole tumor, but positive nuclei were found in limited parts. Occasional stromal or cytoplasmic staining was not evaluated. 47 (10.7%) of the CRC samples displayed tumor cells expressing SOX2 and the expression in relation to different clinicopathological characteristics is shown in [Table 1](#pone-0101957-t001){ref-type="table"}. In our patient cohort, SOX2 expression was found to be significantly associated with a high tumor grade (*p* = 0.004) and TNM stage (*p* = 0.034). SOX2 expression was also highly correlated to *BRAF* mutation (*p*\<0.001), but surprisingly no correlation to *KRAS* mutations could be seen (*p* = 0.928).

![Representative immunohistochemical stainings of SOX2 expression in CRC tissue.\
(A) Negative nuclear SOX2 staining in a moderately differentiated CRC. (B) Positive nuclear SOX2 staining in a poorly differentiated CRC.](pone.0101957.g001){#pone-0101957-g001}

10.1371/journal.pone.0101957.t001

###### SOX2 expression in relation to clinicopathological characteristics in CRC.

![](pone.0101957.t001){#pone-0101957-t001-1}

                                                                           SOX2 negative   SOX2 positive   *p* value[a](#nt102){ref-type="table-fn"}
  ----------------------------------------------------------------------- --------------- --------------- -------------------------------------------
  **Frequencies, n (%)**                                                    394 (89.3)       47 (10.7)    
  **Sex, n (%)**                                                                                                             0.032
  Male                                                                      224 (92.2)       19 (7.8)     
  Female                                                                    170 (85.9)       28 (14.1)    
  **Age, n (%)**                                                                                                             0.548
  ≤59 years                                                                  70 (86.4)       11 (13.6)    
  60--69 years                                                               97 (90.7)       10 (9.3)     
  70--79 years                                                              147 (91.3)       14 (8.7)     
  ≥80 years                                                                  80 (87.0)       12 (13.0)    
  **TNM stage, n (%)** [b](#nt103){ref-type="table-fn"}                                                                      0.034
  I                                                                          62 (93.9)        4 (6.1)     
  II                                                                        153 (92.2)       13 (7.8)     
  III                                                                        81 (89.0)       10 (11.0)    
  IV                                                                         87 (82.1)       19 (17.9)    
  **Localization, n (%)** [b](#nt103){ref-type="table-fn"}                                                                   0.283
  Right colon                                                               122 (85.9)       20 (14.1)    
  Left colon                                                                118 (90.1)       13 (9.9)     
  Rectum                                                                    149 (91.4)       14 (8.6)     
  **Grade, n (%)** [b](#nt103){ref-type="table-fn"}                                                                          0.004
  Highly to moderately differentiated                                       202 (93.5)       14 (6.5)     
  Moderately to poorly differentiated                                       185 (84.9)       33 (15.1)    
  **MSI screening status, n (%)** [b](#nt103){ref-type="table-fn"}                                                           0.725
  MSI                                                                        60 (88.2)       8 (11.8)     
  MSS                                                                       321 (89.7)       37 (10.3)    
  **CIMP status, n (%)** [b](#nt103){ref-type="table-fn"}                                                                    0.193
  CIMP-negative[c](#nt104){ref-type="table-fn"}                             198 (91.7)       18 (8.3)     
  CIMP-low[c](#nt104){ref-type="table-fn"}                                  145 (87.9)       20 (12.1)    
  CIMP-high[c](#nt104){ref-type="table-fn"}                                  47 (83.9)       9 (16.1)     
  ***BRAF^V600E^*** **, n (%)** [b](#nt103){ref-type="table-fn"}                                                            \<0.001
  wild type                                                                 339 (91.4)       32 (8.6)     
  mutated                                                                    47 (75.8)       15 (24.2)    
  ***KRAS*** **(codon 12, 13), n (%)** [b](#nt103){ref-type="table-fn"}                                                      0.928
  wild type                                                                 315 (89.2)       38 (10.8)    
  mutated                                                                    72 (88.9)       9 (11.1)     

Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype (according to an eight-gene CIMP panel).

χ2 test.

The following numbers of missing cases were present: TNM stage, 12; localization, 5; grade, 7; MSI screening status, 15; CIMP status, 4; BRAF V600E, 8; KRAS, 7.

CIMP negative, no promoter hypermethylation; CIMP low, one to five genes methylated; CIMP high, six to eight genes methylated.

SOX2 expression is correlated to a poor patient survival {#s3b}
--------------------------------------------------------

Cancer-specific survival analyses revealed that patients with SOX2 positive tumors had a poorer prognosis than patients with SOX2 negative tumors ([Figure 2a](#pone-0101957-g002){ref-type="fig"}). This association was even stronger when only the *BRAF* mutated tumors was analyzed ([Figure 2b](#pone-0101957-g002){ref-type="fig"}), whilst no difference of SOX2 expression on survival was seen in *BRAF* wild type tumors ([Figure 3c](#pone-0101957-g003){ref-type="fig"}). SOX2 expression did not have any effect on patient prognosis in *KRAS* mutated tumors (*p* = 0.676). In a multivariate Cox proportional hazard model including age, sex, *BRAF* mutation, and SOX2 expression, the poor prognosis for patients with SOX2 expression versus no SOX2 expression retained statistical significance (hazard ratio (HR) = 1.64, 95% CI 1.04--2.58, *p* = 0.032). When further adjusting for stage in the multivariate analysis, the prognostic impact of SOX2 expression was lost (HR = 1.04, 95% CI 0.65--1.67, *p* = 0.878), emphasizing stage dependency.

![Cancer-specific survival analysis according to SOX2 expression.\
Shown are Kaplan-Meier plots of cancer-specific survival in (A) all CRC patients, (B) *BRAF^V600E^* mutated CRC patients or (C) *BRAF* wild type CRC patients.](pone.0101957.g002){#pone-0101957-g002}

![Real Time PCR analyses of SOX2 expression in CRC cell lines.\
(A) Caco2 cells, Caco2 cells stably expressing *BRAF* mutation (Caco2-BRAF^V600E^) and Caco2 cells stably expressing *KRAS* mutation (Caco2-KRAS^G12V^). SOX2 expression in Caco2 was set as 1. (B) Caco2 after cultivation with MEK-inhibitor, 24 or 48 h, or DMSO for 48 h as control. SOX2 expression in Caco2 treated with DMSO was set as 1. (C) Caco2-BRAF^V600E^ after cultivation with MEK-inhibitor, 24 or 48 h, or DMSO for 48 h as control. SOX2 expression in Caco2-BRAF^V600E^ treated with DMSO was set as 1. PD: PD98059 (MEK-inhibitor), \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001, n.s: non-significant *p*-value.](pone.0101957.g003){#pone-0101957-g003}

SOX2 expression is regulated by BRAF *in vitro* {#s3c}
-----------------------------------------------

As SOX2 expression correlated with mutated *BRAF* in our patient cohort, we continued to analyze their molecular relation *in vitro*. The CRC cell line Caco2, with endogenous BRAF and KRAS wild type, was transfected with either BRAF^V600E^ or KRAS^G12V^ in order to establish cell lines stably expressing mutant *BRAF* (Caco2-BRAF^V600E^, [Figure S1a](#pone.0101957.s001){ref-type="supplementary-material"}) or mutant *KRAS* (Caco2-KRAS^G12V^, [Figure S1b](#pone.0101957.s001){ref-type="supplementary-material"}). By RT-PCR analyses we found that Caco2-BRAF^V600E^ expressed about twice as high SOX2-levels compared to Caco2 (*p* = 0.013), an increase which was not seen in Caco2-KRAS^G12V^ ([Figure 3a](#pone-0101957-g003){ref-type="fig"}). These results, in concordance with our data from the patient cohort ([Table 1](#pone-0101957-t001){ref-type="table"}), suggest that the expression of SOX2 is regulated by mutated BRAF. The *BRAF^V600E^* mutation renders BRAF in a constitutively active state, stimulating the MEK/ERK signaling cascade in the absence of extracellular stimuli [@pone.0101957-CantwellDorris1]. Indeed, blocking BRAF downstream signaling in Caco2-BRAF^V600E^ cells using the MEK-inhibitor PD98059, resulted in a decreased expression of SOX2 ([Figure 3c](#pone-0101957-g003){ref-type="fig"}), suggesting that it is mainly the well characterized MEK activating activity of BRAF that regulates SOX2. Furthermore, the low endogenous levels of SOX2 in Caco2 cells were also decreased by the MEK-inhibitor ([Figure 3b](#pone-0101957-g003){ref-type="fig"}), implying that BRAF responding to endogenous activation signals also regulates SOX2 expression. Together these results support the role of BRAF as an upstream regulator of SOX2 expression.

Primary SOX2 positive CRC has SOX2 positive corresponding liver metastasis {#s3d}
--------------------------------------------------------------------------

Given that fact that SOX2 expression is correlated to a worse patient prognosis, we wanted to study SOX2 expression in primary tumors as well as corresponding distant metastasis. For this, 13 patients with archival tissue from both a primary colorectal adenocarcinoma and distant liver metastasis were included in the study and nuclear SOX2 expression was evaluated in epithelial cells. Two of the 13 primary tumors were SOX2 positive, whereas the other eleven tumors were SOX2 negative. Interestingly, SOX2 positive primary tumors were also SOX2 positive in corresponding liver metastasis, while SOX2 negative tumors had SOX2 negative liver metastasis ([Table 2](#pone-0101957-t002){ref-type="table"}). Noteworthy, these SOX2 positive metastasis were morphologically more alike the tumor compartments having SOX2 positive nuclei than the rest of the primary tumor (data not shown).

10.1371/journal.pone.0101957.t002

###### SOX2 expression in primary CRC and corresponding liver metastasis.

![](pone.0101957.t002){#pone-0101957-t002-2}

                       CRC primary tumors  
  ------------------- -------------------- ---
  **SOX2 negative**            11           0
  **SOX2 positive**            0            2

SOX2 enhance expression of FGFR1 {#s3e}
--------------------------------

Deregulation of fibroblast growth factor receptors (FGFRs) is seen in CRC as well as in other cancers [@pone.0101957-Haugsten1], [@pone.0101957-Turner1]. Since it has been suggested that SOX2 regulate the expression of FGFR3 [@pone.0101957-Fang1], we wanted to study if SOX2 altered the expression of the FGFRs in our *in vitro* system.

A cell line overexpressing SOX2 was established by transfecting the CRC cell line Caco2 with SOX2 (Caco2-SOX2, [Figure S2](#pone.0101957.s002){ref-type="supplementary-material"}). The expression of FGFR1-4 was analyzed by RT-PCR in Caco2 cells and Caco2-SOX2 cells. FGFR1 expression was found to be twice as high in Caco2-SOX2 as in Caco2 (*p* = 0.036), while no significant differences were seen regarding FGFR2, FGFR3 or FGFR4 ([Figure 4](#pone-0101957-g004){ref-type="fig"}).

![Expression of FGFR1 is increased in Caco2-SOX2 compared to Caco2.\
Expression of FGFR1, FGFR2, FGFR3 and FGFR4 by RT-PCR analysis in Caco2 cells and Caco2 cells stably overexpressing SOX2 (Caco2-SOX2). The expression in Caco2 was set as 1. \**p*\<0.05, n.s: non-significant *p*-value.](pone.0101957.g004){#pone-0101957-g004}

Discussion {#s4}
==========

In this study we investigated SOX2 expression in CRC in correlation to several clinicopathological and molecular variables and its effect on patient prognosis. 11% of the tumors were SOX2 positive, and the expression correlated to tumor grade, TNM stage and *BRAF* mutation. Additionally, we found that SOX2 expression predicted a poorer patient prognosis in a stage dependent manner, in particular in *BRAF* mutated cases. Finally, we introduce SOX2 as possible regulator of FGFR1 expression.

Because of the asserted involvement of SOX2 in CRC tumorigenesis [@pone.0101957-Liu1] we wanted to study the expression of SOX2 in our patient cohort CRUMS. We found that 11% of the tumors expressed SOX2 and by comparing the expression to different clinicopathological characteristics we could see that SOX2 expression was correlated to poorly differentiated tumors (high grade). This fits with the knowledge that SOX2 is a known stem cell marker, and has been suggested to be expressed in cancer stem cells [@pone.0101957-BasuRoy1], [@pone.0101957-BenPorath1]. As SOX2 often were expressed in a limited part of the tumor, we speculate that these cells might be representing the cancer stem cell niche in these particular tumors. We further found that SOX2 expression was correlated to poor patient prognosis in a stage dependent manner, which is consistent with some previous studies [@pone.0101957-Han1], [@pone.0101957-Tang1], [@pone.0101957-Pham1].

SOX2 has been described by others to enhance the migratory and invasive effect of CRC cells [@pone.0101957-Han1], [@pone.0101957-Fang1] as wells as of other cancer cell types [@pone.0101957-Lou1]--[@pone.0101957-Girouard1], which implies that SOX2 expressing cells might harbor a higher metastatic capacity. In CRC it has also been suggested that the expression of SOX2 can predict tumor metastasis [@pone.0101957-Han1]. However, no studies exist today of SOX2 expression in tumor metastases. Here we have shown that corresponding liver metastases to SOX2 positive primary tumors also harbor SOX2 positive tumor cells. Although these patient tissue specimens were very few, it still indicates that SOX2 positive cells are more likely to migrate. It would of course be both interesting and necessary to study this in a larger patient material for verification. The fact that the SOX2 positive cells only made up a small proportion of the whole tumor, suggests that these cells may display a more invasive phenotype than the surrounding tumor cells. Another supporting evidence for a more invasive behavior of SOX2 positive tumor cells is that the metastases were morphologically more similar to the parts of the tumor with SOX2 positive nuclei. Even though the morphological comparison between primary tumors and metastases could only be studied in two cases, we find it likely that it may reflect specific cells that actually give rise to distant metastases.

SOX2 expression was correlated to *BRAF* mutation in our tissue cohort, but no correlation could be seen between SOX2 expression and *KRAS* mutations. Our *in vitro* finding that an increased SOX2 expression was seen in cells expressing BRAF^V600E^ mutation but not KRAS^G12V^ mutation, confirms this correlation. The RAS/RAF/MAP kinase cascade is a pathway that is implicated in many important cellular functions such as cell growth, division and differentiation [@pone.0101957-Peyssonnaux1], and its included proteins are frequently mutated in CRC. Of all CRCs, 30--40% are mutated in the *KRAS* gene and 5--15% in the *BRAF* gene [@pone.0101957-Eklof1], [@pone.0101957-Baldus1]. These two mutations are believed to be mutually exclusive in CRC [@pone.0101957-Eklof1], [@pone.0101957-Benvenuti1], and they are both associated with poor patient prognosis [@pone.0101957-Eklof1], [@pone.0101957-Samowitz1]--[@pone.0101957-Phipps1]. Although they are involved in the same pathway, we can see that *KRAS* and *BRAF* mutated CRCs have different morphological appearances. It is interesting to speculate that the association of *BRAF* mutation with SOX2 expression might explain part of that morphological difference. We continued to analyze the correlation of BRAF and SOX2 expression in our *in vitro* cell culture system. Indeed, SOX2 expression was found to be upregulated in cells expressing the constitutively active BRAF^V600E^. Furthermore, by blocking BRAF downstream signaling, endogenous SOX2 as well as SOX2 expression induced by BRAF^V600E^ was decreased, demonstrating that SOX2 expression is at least partly regulated by the well characterized BRAF/MEK pathway. To our knowledge, this is the first study showing that SOX2 expression is regulated by BRAF signaling. Another interesting finding was that the negative prognostic effect of SOX2 expression was restricted to *BRAF* mutated patients, which indicates that it is SOX2 expression in combination with *BRAF* mutation that mostly contributes to the poor prognosis.

It is well known that aberrant expression of fibroblast growth factor receptors (FGFRs) can drive tumor progression [@pone.0101957-Haugsten1], [@pone.0101957-Turner1]. The FGFR family is comprised of four genes, and it has been shown that at least the *FGFR3* gene is regulated by SOX2 in CRC [@pone.0101957-Fang1]. Our cell line overexpressing SOX2, Caco2-SOX2, had twice as high FGFR1 expression as Caco2 cells, implying that FGFR1 expression might be regulated by SOX2. Others have shown that overexpression of FGFR1 is found in CRC [@pone.0101957-Jang1] and that it is correlated to liver metastasis [@pone.0101957-Sato1]. A recent study has also suggested that elevated expression of both SOX2 and FGFR1 is correlated to poor prognosis in small cell lung cancer [@pone.0101957-Yang1]. Together, these findings suggest that SOX2 in part through upregulation of FGFR1 might enhance distant spreading of tumor cells to the liver, thereby causing a poorer patient survival. However, additional studies are needed to reveal the role and mechanism of SOX2 and FGFR1 in CRC.

In conclusion, this study shows that SOX2 expression is correlated to a poor prognosis in CRC patients and it identifies for the first time that SOX2 expression partly is regulated by BRAF. These findings in combination with the observed correlation between SOX2 positivity in both primary tumor and corresponding metastasis, suggest that SOX2 positive tumor cells have an enhanced capacity to metastasize.
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